Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Maria Rosario García-Campelo"'
Autor:
Renata Ferrarotto, Ian Anderson, Balazs Medgyasszay, Maria Rosario García‐Campelo, William Edenfield, Trevor M. Feinstein, Jennifer M. Johnson, Sujith Kalmadi, Philip E. Lammers, Alfredo Sanchez‐Hernandez, Yili Pritchett, Shannon R. Morris, Rajesh K. Malik, Tibor Csőszi
Publikováno v:
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Abstract Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transf
Externí odkaz:
https://doaj.org/article/67201ebc01a245ac809c92ab296cf9ee
Autor:
Ignacio Diaz Perez, Andrea Riccardo Filippi, Rafal Dziadziuszko, Maria Rosario García Campelo, W. Sawyer, Jean-Baptiste Paoli
Publikováno v:
Future Oncology. 17:4657-4663
Consolidation durvalumab is standard of care in patients with unresectable, stage III non-small-cell lung cancer (NSCLC) without disease progression following chemoradiotherapy (the 'PACIFIC regimen'). However, many patients with poor performance sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cd528738a6edc6a0bf172151b67be4b
https://doi.org/10.2217/fon-2021-0952
https://doi.org/10.2217/fon-2021-0952
Autor:
Rajesh K. Malik, Yili Pritchett, Jennifer Johnson, Balazs Medgyasszay, Shannon R. Morris, Renata Ferrarotto, Trevor M. Feinstein, William Jeffery Edenfield, Maria Rosario García-Campelo, Ian Anderson, Tibor Csőszi, Alfredo Sanchez-Hernandez, Sujith Kalmadi, Philip E. Lammers
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Cancer Medicine, Vol 10, Iss 17, Pp 5748-5756 (2021)
Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs), erythropoiesis‐stimulating agents (ESAs), and red blood cell (RBC) transfusions, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02186969879d8ae63ae2a1d68491ab2f
http://europepmc.org/articles/PMC8419768
http://europepmc.org/articles/PMC8419768
Autor:
Igor Gomez-Randulfe, Sofía Silva Díaz, Carles Escriu, Saara Mohammed, Riyaz Shah, Javier David Benitez Fuentes, Samantha Cox, Federico Monaca, Emilio Bria, María Rosario García-Campelo, Benjamin Crook, Toby Talbot, Rita Leporati, Kirsty Balachandran, Tom Newsom-Davis, Sarah Hughes, Laura Cove-Smith, Paul Taylor, Fiona Blackhall, Raffaele Califano
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background and objectives: Second-line treatment for small-cell lung cancer (SCLC) is primarily guided by the time elapsed since the last platinum dose. Rechallenge with carboplatin and etoposide has demonstrated superior outcomes compared to topotec
Externí odkaz:
https://doaj.org/article/b761da8d4bca4511a117872a9490eebc